US20060241190A1 - Keratolytic composition with anti-allergic anti-inflammatory properties - Google Patents
Keratolytic composition with anti-allergic anti-inflammatory properties Download PDFInfo
- Publication number
- US20060241190A1 US20060241190A1 US10/551,001 US55100105A US2006241190A1 US 20060241190 A1 US20060241190 A1 US 20060241190A1 US 55100105 A US55100105 A US 55100105A US 2006241190 A1 US2006241190 A1 US 2006241190A1
- Authority
- US
- United States
- Prior art keywords
- composition
- chloride
- cosmetic composition
- enhanced medicinal
- ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the present invention relates to a pharmaceutical composition as well as pharmaceutical and/or cosmetic preparation that is effective for the treatment of psoriasis and like skin disorders.
- Allergens are substances from foods, plants, environment or animals that inflame the skin because the immune system over-reacts to these substance. Inflammation occurs even when the person is exposed to very small amounts of the substance for a limited period of time.
- Some examples of allergens are pollen and pet's dander (tiny particles from the animal's skin or hair).
- Allergic reactions are classified into from type I to type IV depending on the causative immunoglobulins and cells participating therein.
- the types I to III allergies are immunological reactions in which human antibodies participate. They are called immediate-type allergies, since allergic reactions appear immediately upon contact.
- the type IV allergy is a cell-mediated immunological reaction in which instead of an antibody, sensitized lymphocytes participate. It is also called delayed-type allergy.
- Allergic reaction of type IV is a reaction of a delayed type in which T cells (small white blood cells that orchestrate and/or directly participate in the immune defenses, also known as T lymphocytes) receiving an antigen information via antigen-presenting cells and release various cytokines whereby an inflammation reaction of a delayed type takes place.
- Allergic contact dermatitis is a typical disease, which occurs due to an allergic reaction of type IV.
- Steroid compositions are used for the therapy of allergic diseases of type IV and such steroid compositions suppress the production of cytokine in T cells and show a dramatic effect for the therapy of eczema.
- cytokine in T cells
- eczema On the other hand however, there is a possibility that they cause severe adverse actions such as thinning/sensitizing of skin, sleeplessness, photosensitivity, decrease in adrenocortical function etc by long period administration.
- psoriasis An example of an allergic and immunology mediated skin disease is psoriasis.
- psoriasis is likely a disorder of the immune system.
- This system includes a type of white blood cell, called a T cell, that normally helps protect the body against infection and disease.
- T cells a type of white blood cell, called a T cell, that normally helps protect the body against infection and disease.
- T cells white blood cell
- T cells trigger the inflammation and excessive skin cell reproduction seen in people with psoriasis.
- Many of the pathological and histological findings of this disease are equivalent to those of dermatitis (eczema).
- Psoriasis is frequently worsened and becomes chronic by external stimulus. In each case, it is the fundamental therapy to control the skin symptoms to thereby prevent worsening.
- Psoriasis treatments for Psoriasis are corticosteroids, calcipotriene, anthralin, topical retinoid, coal tar, salicylic acid etc. All of these treatments have side effects and become ineffective when used in for long period of time.
- compositions for allergic and immunology skin diseases have already been developed and being used for the therapy but, they have adverse reactions hence, there has been a strong demand for compositions derived from natural products where a long-term administration is possible, safety is high and no adverse reaction takes place.
- This invention provides a therapeutic and preventive composition for allergic and immunology skin diseases which has no adverse action, shows a high safety even by a long-term administration and is able to be utilized for pharmaceutical and/or cosmetic preparation and cosmetic composition which are used daily.
- the present invention relates to a pharmaceutical composition as well as pharmaceutical and/or cosmetic preparation containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective ingredient and, more particularly, it relates topical preparation having an action of keratolytic and/or suppressing the immediate-type and delayed-type allergy and/or reducing inflamation, to a pharmaceutical composition with an object of improving the allergy and to a cosmetic composition containing the same.
- This invention provides a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases, such as psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff etc, which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized as pharmaceutical and/or cosmetics, etc. which are used daily.
- allergic and/or autoimmune skin diseases such as psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff etc, which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized as pharmaceutical and/or cosmetics, etc. which are used daily.
- topical application provides keratolytic effect along with anti-allergic and anti-inflammatory effect and it is characterized in containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective and/or active ingredient; an anti-allergic composition for topical administration or an anti-inflammatory composition for topical administration which is characterized in containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective and/or active ingredient to pharmaceutical and/or cosmetic preparation for it is useful in preventing, reducing or relieving allergic symptoms and/or inflammatory symptoms.
- Natural vanilla has used for generations as flavoring in foods, drinks and medicines. Vanilla beans were an antidote for certain venomous bites. It was used for respiratory pain and congestion, deep coughs, stomach ailments etc. Presently vanilla finds its way mostly into food, cosmetic and medicines as flavoring agent and into perfumes and some medicines for its aromatic properties as mood enhancer/stimulant.
- vanilla extract when used in the cleansing liquid where quantity is very minimal (say ⁇ 2%) it exhibits an anti-allergic and anti-inflammatory effect on the skin in patients who suffer with psoriasis.
- Most of the cleansing agents contain sodium chloride and/or ammonium chloride and/or potassium chloride.
- ammonium chloride is used along with other gentle surfactants like sodium laureth sulfate and ammonium laureth sulfate it was showing keratolytic properties by removing scales in psoriasis effected patients.
- the same test has been repeated by using sodium chloride in the place of ammonium chloride and found that it was not having keratolytic properties.
- Ammonium chloride is being used presently in the cleansing liquids etc, but it has not been used as an ingredient specifically to provide a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases.
- ammonium chloride other quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, stearalkonium chloride, and the like can be used to like effect.
- cleansing composition containing ammonium chloride and/or ammonium surfactants and/or quarternary ammonium compounds exhibited keratolytic properties.
- Composition started showing anti-allergic and anti-inflammatory properties when natural vanilla extract was used in the composition.
- composition exhibited better results when moisturizing natural extracts and/or oils like chamomile, sunflower, coconut etc are used in the composition preparation.
- vanilla, ammonium chloride and/or ammonium surfactants and/or quarternary ammonium compounds and other natural extracts like chamomile, sunflower, coconut etc exhibit keratolytic effect along with anti-allergic and anti-inflammatory effects and moisturizing the skin.
- This invention is lead by desire for developing a new and innovative treatment, which can be used in the longer periods of time without side effect associated with other products.
- the Topical Composition given in the example being used for more than 6 months and also tested on other psoriasis patients with encouraging results.
- compositions are convenient to use, cost effective compared to other preparations and most of all these can be used for longer periods of time without side effects.
- the responsive time to the treatment may be different for each individual patient and depends upon the severity of the lesions. Typically some improvement is visible after 3-4 days after initiation of treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A product with an enhanced medicinal and cosmetic composition with a specific utility of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.
Description
- The present invention relates to a pharmaceutical composition as well as pharmaceutical and/or cosmetic preparation that is effective for the treatment of psoriasis and like skin disorders.
- Epidemiological surveys have indicated an increase in allergic diseases. The increase in these allergic diseases has become a big social and economical problem and people and governments are losing time and money, besides having psychological affects.
- It is believed that changes of environmental surroundings are the main cause for these diseases. Environmental changes such as migration to new places and climates, westernization of food, pollution, food additives, excessive use of cosmetics and medicines, excessive stress are the causes of an increase in such allergic symptoms.
- Allergens are substances from foods, plants, environment or animals that inflame the skin because the immune system over-reacts to these substance. Inflammation occurs even when the person is exposed to very small amounts of the substance for a limited period of time. Some examples of allergens are pollen and pet's dander (tiny particles from the animal's skin or hair).
- Allergic reactions are classified into from type I to type IV depending on the causative immunoglobulins and cells participating therein. The types I to III allergies are immunological reactions in which human antibodies participate. They are called immediate-type allergies, since allergic reactions appear immediately upon contact.
- The type IV allergy is a cell-mediated immunological reaction in which instead of an antibody, sensitized lymphocytes participate. It is also called delayed-type allergy. Allergic reaction of type IV is a reaction of a delayed type in which T cells (small white blood cells that orchestrate and/or directly participate in the immune defenses, also known as T lymphocytes) receiving an antigen information via antigen-presenting cells and release various cytokines whereby an inflammation reaction of a delayed type takes place.
- Allergic contact dermatitis is a typical disease, which occurs due to an allergic reaction of type IV. Steroid compositions are used for the therapy of allergic diseases of type IV and such steroid compositions suppress the production of cytokine in T cells and show a dramatic effect for the therapy of eczema. On the other hand however, there is a possibility that they cause severe adverse actions such as thinning/sensitizing of skin, sleeplessness, photosensitivity, decrease in adrenocortical function etc by long period administration.
- An example of an allergic and immunology mediated skin disease is psoriasis. Recent researches indicate that psoriasis is likely a disorder of the immune system. This system includes a type of white blood cell, called a T cell, that normally helps protect the body against infection and disease. Scientists now believe that, in psoriasis, an abnormal immune system causes activity by T cells in the skin. These T cells trigger the inflammation and excessive skin cell reproduction seen in people with psoriasis. Many of the pathological and histological findings of this disease are equivalent to those of dermatitis (eczema). Psoriasis is frequently worsened and becomes chronic by external stimulus. In each case, it is the fundamental therapy to control the skin symptoms to thereby prevent worsening.
- Common treatments for Psoriasis are corticosteroids, calcipotriene, anthralin, topical retinoid, coal tar, salicylic acid etc. All of these treatments have side effects and become ineffective when used in for long period of time.
- Pharmaceutical compositions for allergic and immunology skin diseases have already been developed and being used for the therapy but, they have adverse reactions hence, there has been a strong demand for compositions derived from natural products where a long-term administration is possible, safety is high and no adverse reaction takes place.
- This invention provides a therapeutic and preventive composition for allergic and immunology skin diseases which has no adverse action, shows a high safety even by a long-term administration and is able to be utilized for pharmaceutical and/or cosmetic preparation and cosmetic composition which are used daily.
- The present invention relates to a pharmaceutical composition as well as pharmaceutical and/or cosmetic preparation containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective ingredient and, more particularly, it relates topical preparation having an action of keratolytic and/or suppressing the immediate-type and delayed-type allergy and/or reducing inflamation, to a pharmaceutical composition with an object of improving the allergy and to a cosmetic composition containing the same.
- This invention provides a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases, such as psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff etc, which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized as pharmaceutical and/or cosmetics, etc. which are used daily. To be specific, topical application provides keratolytic effect along with anti-allergic and anti-inflammatory effect and it is characterized in containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective and/or active ingredient; an anti-allergic composition for topical administration or an anti-inflammatory composition for topical administration which is characterized in containing vanilla extract/oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective and/or active ingredient to pharmaceutical and/or cosmetic preparation for it is useful in preventing, reducing or relieving allergic symptoms and/or inflammatory symptoms.
- Natural vanilla has used for generations as flavoring in foods, drinks and medicines. Vanilla beans were an antidote for certain venomous bites. It was used for respiratory pain and congestion, deep coughs, stomach ailments etc. Presently vanilla finds its way mostly into food, cosmetic and medicines as flavoring agent and into perfumes and some medicines for its aromatic properties as mood enhancer/stimulant.
- In the beginning of 1900s it was observed that workers who handled the pods of Vanilla Planifolia have developed dermatitis of the hands and face. Similar finding have been report by many others like Hutchinson (1892), Maiden (1912), White (1934), Downing (1939). This dermatitis was named as ‘Vanillasim’. May be because of these finding it was never been used to cure any skin diseases. But most of the above findings are based on actual handling of vanilla pods, vines, plants.
- In the present invention it has been found that when vanilla extract is used in the cleansing liquid where quantity is very minimal (say <2%) it exhibits an anti-allergic and anti-inflammatory effect on the skin in patients who suffer with psoriasis.
- Most of the cleansing agents contain sodium chloride and/or ammonium chloride and/or potassium chloride. In the present invention it was found that when ammonium chloride is used along with other gentle surfactants like sodium laureth sulfate and ammonium laureth sulfate it was showing keratolytic properties by removing scales in psoriasis effected patients. The same test has been repeated by using sodium chloride in the place of ammonium chloride and found that it was not having keratolytic properties.
- Ammonium chloride is being used presently in the cleansing liquids etc, but it has not been used as an ingredient specifically to provide a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases. In addition to ammonium chloride other quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, stearalkonium chloride, and the like can be used to like effect.
- Though the actual mechanism is not understood, it was tested on 5 different patients with different climatic conditions and observed that cleansing composition containing ammonium chloride and/or ammonium surfactants and/or quarternary ammonium compounds exhibited keratolytic properties. Composition started showing anti-allergic and anti-inflammatory properties when natural vanilla extract was used in the composition.
- It was also observed that composition exhibited better results when moisturizing natural extracts and/or oils like chamomile, sunflower, coconut etc are used in the composition preparation.
- It was observed that vanilla, ammonium chloride and/or ammonium surfactants and/or quarternary ammonium compounds and other natural extracts like chamomile, sunflower, coconut etc exhibit keratolytic effect along with anti-allergic and anti-inflammatory effects and moisturizing the skin.
- In order to illustrate the invention in detail, representative Examples will be given as hereunder although the invention is not limited thereto.
- For Scalp Cleansing Composition:
Ammonium Laureth Sulfate 28-30% Sodium Laureth Sulfate 1-2% Coamidopropylbetain 2-3% Ammonium Chloride 0.50-1% Tetrasodium EDTA 0.25-1% DMD Hydantoin 0.10-0.40% Citric Acid 0.10-0.40% Dye 0.20-0.40% Vanilla Extract 0.10-0.30% Chamomile Extract 0.10-0.30% Sunflower Extract 0.10-0.30% Deionised water To make quantity to 100% - For Scalp Cream:
Ammonium Chloride 0.50-2% Potassium Chloride 0.50-2% Citric Acid 0.10-2% Vanilla Extract 0.10-0.50% Chamomile Extract 0.10-0.50% Coconut Oil 10-20% Starch 20-30% White Soft Paraffin 30-40% Phenoxyethanol 1-3% Deionised water To make quantity to 100% - For Body Lotion:
Ammonium Chloride 0.50-2% Potassium Chloride 0.50-2% Citric Acid 0.10-2% Vanilla Extract 0.10-0.50% Chamomile Extract 0.10-0.50% Phenol 0.10-0.50% Talcum 15-20% Zinc Oxide 5-10% Glycerin 7.5-15% Alcohol 20-30% Deionised water To make quantity to 100% - Inventor himself is a psoriasis patient for the last 8 years. He tried all topical applications like salicylic acid, coal tar, steroid based etc and experienced all sorts of side effects associated with these presently available treatments.
- This invention is lead by desire for developing a new and innovative treatment, which can be used in the longer periods of time without side effect associated with other products. The Topical Composition given in the example being used for more than 6 months and also tested on other psoriasis patients with encouraging results.
- These compositions are convenient to use, cost effective compared to other preparations and most of all these can be used for longer periods of time without side effects.
- The responsive time to the treatment may be different for each individual patient and depends upon the severity of the lesions. Typically some improvement is visible after 3-4 days after initiation of treatment.
- Though the exact mechanism of action of quaternary ammonium compounds, such as ammonium chloride, and vanilla is not fully understood, actual testing on psoriasis patients have shown encouraging results without side effects associated with steroids and other presently available psoriasis topical applications.
- It is also understood that each of above active ingredients described above, or two or more together may also find a useful application in other types of methods differing from the type described above.
- While certain novel features of this invention have been shown and described and mentioned in the claims, it is not intended to be limited to the details above, since it will be understood that various omissions, modifications, substitutions and changes in the forms and details of the device illustrated and in its operation can be made by those skilled in the art without departing in any way from the spirit of the present invention.
Claims (15)
1. An enhanced medicinal and cosmetic composition of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla exact, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.
2. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein the composition contains Vanilla Extract, Ammonium Chloride, Potassium Chloride as its active agents and ingredients, one or more together, in a therapeutically effective amount for treating skin disorders like Psoriasis, Eczema.
3. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein the composition is characterized in containing vanilla extract means vanilla extract or oil or vanillin selected from natural or synthetic vanilla and derivatives thereof as an effective and active ingredient.
4. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein the composition is used as a keratolytic composition, anti-allergic composition and anti-inflammatory composition.
5. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein topical administration is in the form of lotion, cream, ointment, emulsion, solution, patch, pad, cleanser, conditioner, gel, soap, sprays, foam and tape.
6. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein the composition is for usage of men, women and children who are suffering with skin disorders.
7. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein contains natural Vanilla extract and oil extracted from flowers, fruit, pods, beans, seeds, vine of species in the orchid family, Orchidacae, like vanilla planifolia, vanilla tahitensis.
8. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein is used for the treatment of skin disorders like psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff.
9. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein quaternary ammonium compounds like benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridium chloride, glycidyl trimethyl, stearalkonium chloride, ammonium laureth sulphate, ammonium luryl sulphate is being added for further enhancement.
10. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein a cation chloride salt like ammonium chloride, potassium chloride is being added for further enhancement.
11. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein wherein a quaternary ammonium compounds like benzalkonium chloride, stearalkonium chloride, ammonium laureth sulphate, ammonium luryl sulphate is present in an amount of from about 0.001% to about 40% by weight of said composition, more preferably from about 10% to about 30% by weight of said composition.
12. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein a cation chloride salt like ammonium chloride, potassium chloride etc is present in an amount of from about 0.001% to about 10% by weight of said composition, more preferably from about 0.5% to about 4% by weight of said composition.
13. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein the composition is adjusted to a pH of greater than about 3.0 and less than about 7.0 and more preferably greater than about 4.0 and less than about 6.0 in the final composition.
14. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein A method of treating skin disorders comprising administration to an area of skin disorder a suitable carrier containing vanilla extract or oil in a therapeutically effective amount.
15. An enhanced medicinal and cosmetic composition as claimed in claim (1), wherein contains a cation chloride salt like ammonium chloride, potassium chloride etc which also represents salts made as per the any Systems of Medicines like Ayurveda, Siddha, Unam and Homeopathic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/571,054 US10179148B2 (en) | 2003-03-27 | 2014-12-15 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN185/KOL/2003 | 2003-03-27 | ||
IN185KO2003 | 2003-03-27 | ||
PCT/IN2004/000069 WO2004084855A1 (en) | 2003-03-27 | 2004-03-26 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2004/000069 A-371-Of-International WO2004084855A1 (en) | 2003-03-27 | 2004-03-26 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/571,054 Continuation US10179148B2 (en) | 2003-03-27 | 2014-12-15 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060241190A1 true US20060241190A1 (en) | 2006-10-26 |
Family
ID=33042621
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/551,001 Abandoned US20060241190A1 (en) | 2003-03-27 | 2004-03-26 | Keratolytic composition with anti-allergic anti-inflammatory properties |
US14/571,054 Active 2026-03-17 US10179148B2 (en) | 2003-03-27 | 2014-12-15 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/571,054 Active 2026-03-17 US10179148B2 (en) | 2003-03-27 | 2014-12-15 | Keratolytic composition with anti-allergic anti-inflammatory properties |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060241190A1 (en) |
EP (1) | EP1620063B1 (en) |
JP (1) | JP4955382B2 (en) |
KR (1) | KR101204581B1 (en) |
CN (1) | CN1774236B (en) |
AT (1) | ATE496610T1 (en) |
AU (1) | AU2004224521A1 (en) |
CA (1) | CA2520307A1 (en) |
DE (1) | DE602004031208D1 (en) |
EA (1) | EA011947B1 (en) |
ES (1) | ES2360290T3 (en) |
WO (1) | WO2004084855A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150072026A1 (en) * | 2013-09-07 | 2015-03-12 | Yunyuan Li | Anti-inflammatory ion and uses thereof |
WO2018083675A1 (en) | 2016-11-07 | 2018-05-11 | Jubilant Life Sciences Limited | Synergistic antimicrobial compositions |
US9968537B2 (en) | 2013-09-06 | 2018-05-15 | Jubilant Life Sciences Limited | Anti-dandruff compositions and hair care formulations containing zinc pyrithione and quaternary ammonium salt |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006054312A1 (en) * | 2004-11-16 | 2006-05-26 | Munisekhar Medasani | Ammonium compounds for treating psoriasis and eczema |
US8709502B2 (en) | 2005-09-23 | 2014-04-29 | Chanel Parfums Beaute | Extract of Vanilla planifolia |
JP5300480B2 (en) * | 2005-09-23 | 2013-09-25 | シャネル パルファン ボーテ | Vanilla planifolia extract, extraction process thereof, and cosmetic composition or dermatological composition containing the same |
FR2891148B1 (en) * | 2005-09-23 | 2008-03-28 | Chanel Parfums Beaute Soc Par | VANILLA EXTRACT, PROCESS FOR OBTAINING THE SAME, AND COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING THE SAME |
GB0526283D0 (en) | 2005-12-23 | 2006-02-01 | Givaudan Sa | Compositions |
JP2008174495A (en) * | 2007-01-19 | 2008-07-31 | Reverse Proteomics Research Institute Co Ltd | Target protein and target gene for use in drug development and method for screening the same |
FR2973227B1 (en) * | 2011-04-01 | 2014-08-08 | Oreal | COSMETIC COMPOSITION COMPRISING 4- (3-ETHOXY-4-HYDROXYPHENYL) BUTAN-2-ONE |
CN103784641A (en) * | 2014-02-08 | 2014-05-14 | 张孝昌 | Traditional Chinese medicine for treating psoriasis |
CN103977262A (en) * | 2014-06-06 | 2014-08-13 | 马朝富 | Pure traditional Chinese medicinal preparation for treating pulmonary tuberculosis and preparation method thereof |
EP3011959A1 (en) | 2014-10-23 | 2016-04-27 | Santen SAS | Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha |
US20190000822A1 (en) * | 2016-02-24 | 2019-01-03 | Nicolae Arcasiu | Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis |
CN114788791A (en) | 2017-06-23 | 2022-07-26 | 宝洁公司 | Compositions and methods for improving the appearance of skin |
PL233723B1 (en) * | 2017-09-12 | 2019-11-29 | Politechnika Lodzka | Natural care cream for seborrheic, acne prone skin |
CN107582926A (en) * | 2017-09-26 | 2018-01-16 | 黄经卫 | One kind treats psoriasic Chinese medicine composition |
CN112437657A (en) | 2018-07-03 | 2021-03-02 | 宝洁公司 | Method of treating skin conditions |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
US4822604A (en) * | 1985-05-20 | 1989-04-18 | S. C. Johnson & Son, Inc. | Local treatment of dandruff, seborrheic dermatitis, and psoriasis |
US5104645A (en) * | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
US5607980A (en) * | 1995-07-24 | 1997-03-04 | The Procter & Gamble Company | Topical compositions having improved skin feel |
US5680962A (en) * | 1994-11-16 | 1997-10-28 | Mceleney; John | Lotion which is temporarily colored upon application |
US5997889A (en) * | 1998-02-20 | 1999-12-07 | Omnipotent Skin Products, L.L.C. | Hand and body creme for the treatment of skin ailments |
US20010018059A1 (en) * | 1999-01-08 | 2001-08-30 | Gehlsen Kurt R. | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US20020111280A1 (en) * | 2000-09-08 | 2002-08-15 | Norbert Trage | Care agents |
US20020168423A1 (en) * | 1997-12-19 | 2002-11-14 | Wurzburger Stephen Ray | High strength liquid antiseptic |
US20020173436A1 (en) * | 2000-09-20 | 2002-11-21 | Steffen Sonnenberg | Multiphase soaps |
US6585983B1 (en) * | 1998-09-18 | 2003-07-01 | Beiersdorf Ag | Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3212970A (en) * | 1960-02-04 | 1965-10-19 | Glasser Joseph | Treatment of psoriasis |
JP4299374B2 (en) * | 1996-10-08 | 2009-07-22 | 高砂香料工業株式会社 | Cell activator and its application |
US20030104018A1 (en) * | 1996-12-31 | 2003-06-05 | Griscom Bettle | Skin product having micro-spheres, and processes for the production thereof |
JPH1160456A (en) * | 1997-08-18 | 1999-03-02 | Maguoole Sci Kk | Bathing agent for skin and skin preparation for external use and body soap |
GB9727053D0 (en) | 1997-12-22 | 1998-02-18 | Edko Trading Representation | Pharmaceutical compositions |
WO2000000186A1 (en) * | 1998-06-30 | 2000-01-06 | American Medical Research, Inc. | Method of treating topical ailments |
JP2000319171A (en) * | 1999-03-03 | 2000-11-21 | Nof Corp | Bactricidal skin lotion composition |
EP1250915A1 (en) * | 2001-04-19 | 2002-10-23 | Beiersdorf Aktiengesellschaft | Cosmetic and dermatologic compositions comprising high electrolyt contents |
-
2004
- 2004-03-26 EA EA200501439A patent/EA011947B1/en not_active IP Right Cessation
- 2004-03-26 DE DE602004031208T patent/DE602004031208D1/en not_active Expired - Lifetime
- 2004-03-26 CA CA002520307A patent/CA2520307A1/en not_active Abandoned
- 2004-03-26 AU AU2004224521A patent/AU2004224521A1/en not_active Abandoned
- 2004-03-26 WO PCT/IN2004/000069 patent/WO2004084855A1/en active Application Filing
- 2004-03-26 KR KR1020057018005A patent/KR101204581B1/en not_active IP Right Cessation
- 2004-03-26 ES ES04723696T patent/ES2360290T3/en not_active Expired - Lifetime
- 2004-03-26 EP EP04723696A patent/EP1620063B1/en not_active Expired - Lifetime
- 2004-03-26 CN CN2004800101098A patent/CN1774236B/en not_active Expired - Fee Related
- 2004-03-26 US US10/551,001 patent/US20060241190A1/en not_active Abandoned
- 2004-03-26 AT AT04723696T patent/ATE496610T1/en not_active IP Right Cessation
- 2004-03-26 JP JP2006507627A patent/JP4955382B2/en not_active Expired - Fee Related
-
2014
- 2014-12-15 US US14/571,054 patent/US10179148B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4822604A (en) * | 1985-05-20 | 1989-04-18 | S. C. Johnson & Son, Inc. | Local treatment of dandruff, seborrheic dermatitis, and psoriasis |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
US5104645A (en) * | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
US5680962A (en) * | 1994-11-16 | 1997-10-28 | Mceleney; John | Lotion which is temporarily colored upon application |
US5607980A (en) * | 1995-07-24 | 1997-03-04 | The Procter & Gamble Company | Topical compositions having improved skin feel |
US20020168423A1 (en) * | 1997-12-19 | 2002-11-14 | Wurzburger Stephen Ray | High strength liquid antiseptic |
US5997889A (en) * | 1998-02-20 | 1999-12-07 | Omnipotent Skin Products, L.L.C. | Hand and body creme for the treatment of skin ailments |
US6585983B1 (en) * | 1998-09-18 | 2003-07-01 | Beiersdorf Ag | Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type |
US20010018059A1 (en) * | 1999-01-08 | 2001-08-30 | Gehlsen Kurt R. | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US20020111280A1 (en) * | 2000-09-08 | 2002-08-15 | Norbert Trage | Care agents |
US20020173436A1 (en) * | 2000-09-20 | 2002-11-21 | Steffen Sonnenberg | Multiphase soaps |
Non-Patent Citations (1)
Title |
---|
Sunburn 2012 http://emedicine.medscape.com/article/773203-overview * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9968537B2 (en) | 2013-09-06 | 2018-05-15 | Jubilant Life Sciences Limited | Anti-dandruff compositions and hair care formulations containing zinc pyrithione and quaternary ammonium salt |
US20150072026A1 (en) * | 2013-09-07 | 2015-03-12 | Yunyuan Li | Anti-inflammatory ion and uses thereof |
WO2018083675A1 (en) | 2016-11-07 | 2018-05-11 | Jubilant Life Sciences Limited | Synergistic antimicrobial compositions |
Also Published As
Publication number | Publication date |
---|---|
KR101204581B1 (en) | 2012-11-26 |
JP2008500261A (en) | 2008-01-10 |
AU2004224521A1 (en) | 2004-10-07 |
EA011947B1 (en) | 2009-06-30 |
US20150164941A1 (en) | 2015-06-18 |
DE602004031208D1 (en) | 2011-03-10 |
JP4955382B2 (en) | 2012-06-20 |
CN1774236A (en) | 2006-05-17 |
EA200501439A1 (en) | 2006-04-28 |
ATE496610T1 (en) | 2011-02-15 |
EP1620063A1 (en) | 2006-02-01 |
WO2004084855A1 (en) | 2004-10-07 |
EP1620063B1 (en) | 2011-01-26 |
CA2520307A1 (en) | 2004-10-07 |
ES2360290T3 (en) | 2011-06-02 |
KR20060007007A (en) | 2006-01-23 |
US10179148B2 (en) | 2019-01-15 |
CN1774236B (en) | 2013-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10179148B2 (en) | Keratolytic composition with anti-allergic anti-inflammatory properties | |
US6974596B2 (en) | Interleukin-4 production inhibitors | |
WO1997015280A1 (en) | Use of at least one no synthase inhibitor for treating sensitive skin | |
US20200338105A1 (en) | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting | |
Tiwari et al. | Development and evaluation of herbal hair serum: A traditional way to improve hair quality | |
CN103313693A (en) | Method for stimulating hair growth | |
JP2006321758A (en) | Cosmetic | |
Karacic et al. | A single application of crotamiton lotion in the treatment of patients with pediculosis capitis | |
US20200215118A1 (en) | Pharmaceutical composition for treatment of atopy containing exosomes derived from neural stem cells | |
JP2001233723A (en) | Cosmetic set for mind and body | |
WO2019162788A1 (en) | Composition for use in the treatment of seborrheic dermatitis | |
Slade et al. | Clinical efficacy evaluation of a novel barrier protection cream | |
WO2006054312A1 (en) | Ammonium compounds for treating psoriasis and eczema | |
KR20190092822A (en) | A composition for improving and treating skin disease comprising aptamin C as effective component | |
Pigatto et al. | Allergic contact dermatitis from Tektamer 38®(dibromocyanobutane). | |
KR20210147232A (en) | Composition for Improving Acne | |
Kellen et al. | Adolescent Seborrhoeic Dermatitis | |
WO2009145654A1 (en) | Preparation for care and protection of skin with children and adults, method for obtaining thereof | |
JPS63313715A (en) | Hair growth stimulating composition | |
JP2000119126A (en) | Effective composition for vital environment | |
JP2002097135A (en) | Skin care preparation for ameliorating damage of circulatory organ caused by stress | |
RU2611347C1 (en) | Personal hygiene agent with acaricidal activity on mite demodex | |
Belsito et al. | Safety Assessment of Quaternium-18 and Quaternium-18 Bentonite as Used in Cosmetics | |
Lyapina et al. | Gallates–toxicological data and a pilot study on the prevalence of contact sensitization | |
Shastry | Genetic susceptibility to normal tension glaucoma (NTG) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |